July 20, 2015 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Receptos Inc (NASDAQ:RCPT), was announced concerning whether the takeover of Receptos by Celgene Corporation for $232.00 per share is unfair to NASDAQ:RCPT stockholders.

The investigation by a law firm concerns whether certain officers and directors of Receptos Inc breached their fiduciary duties owed to NASDAQ:RCPT investors in connection with the proposed acquisition.

On July 14, 2015, Celgene Corporation (NASDAQ: CELG) and Receptos Inc (NASDAQ:RCPT) announced the signing of an agreement in which Celgene has agreed to acquire Receptos. Under the terms of the merger agreement, Celgene will pay $232.00 per share in cash, or a total of approximately $7.2 billion, net of cash acquired.

However, given that at least one analyst has set the high target price for NASDAQ:RCPT shares at $348 per share, the investigation concerns whether the offer is unfair to NASDAQ:RCPT stockholders. More specifically, the investigation concerns whether the Receptos Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.